Pediatrix Medical Group (NYSE:MD) Issues Earnings Results, Beats Expectations By $0.07 EPS

Key Points

• Pediatrix beat Q1 estimates, reporting $0.44 EPS vs. $0.37 expected and revenue of $476.2M, up 3.9% year-over-year.
• Management posted adjusted EBITDA of $58M and reaffirmed full-year adjusted EBITDA guidance of $280–$300M, but warned RCM-driven pricing gains may moderate and same-unit NICU volumes fell about 1%, a potential downside risk.
• The company ended the quarter with just over $200M in cash, net debt of roughly $385M (~1.3x leverage) and repurchased $21M of stock, while the share price fell about 7.4% intraday to $20.75.

Pediatrix Medical Group (NYSE:MD - Get Free Report) issued its earnings results on Tuesday. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07, FiscalAI reports. The company had revenue of $476.20 million for the quarter, compared to analysts' expectations of $465.83 million. Pediatrix Medical Group had a net margin of 8.64% and a return on equity of 19.59%. The firm's quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.33 EPS.

Here are the key takeaways from Pediatrix Medical Group's conference call:

• Pediatrix reported a strong Q1 with adjusted EBITDA of $58 million driven by top-line growth and 4% pricing, and management reaffirmed the full-year adjusted EBITDA outlook of $280–$300 million.
• Pricing growth (~4%) was driven by RCM cash collections (about 25% of the quarter's pricing lift), contract admin fees (10–20%), favorable payer mix and higher neonatology acuity, but management expects RCM-driven gains to moderate and is maintaining a flat pricing outlook for the year.
• Same-unit volumes showed modest declines (NICU days down ~1%), and although management says there is no clear multiquarter trend yet, sustained volume weakness would be a downside risk to revenue and EBITDA.
• Balance sheet and capital allocation activity remain constructive—Q1 used ~$130 million of operating cash (seasonal incentive payouts), repurchased $21 million of stock, ended the quarter with just over $200 million cash and net debt of just over $385 million (~1.3x net leverage at midpoint).
• Leadership and strategic moves emphasize quality and growth—Pediatrix hired two high-profile clinical quality leaders, launched a clinician partner equity program, and is targeting expanded telehealth and OB/MFM services to deepen hospital partnerships.

Pediatrix Medical Group Stock Down 7.4%

NYSE:MD traded down $1.66 during mid-day trading on Tuesday, hitting $20.75. 750,769 shares of the company's stock traded hands, compared to its average volume of 775,567. The company has a fifty day moving average of $20.96 and a 200 day moving average of $21.21. Pediatrix Medical Group has a twelve month low of $11.84 and a twelve month high of $24.99. The company has a market capitalization of $1.72 billion, a P/E ratio of 10.70 and a beta of 0.70. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.66 and a current ratio of 1.66.

Institutional Investors Weigh In On Pediatrix Medical Group

A number of large investors have recently modified their holdings of the business. Ameriprise Financial Inc. raised its position in shares of Pediatrix Medical Group by 175.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 744,473 shares of the company's stock valued at $10,683,000 after purchasing an additional 474,186 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Pediatrix Medical Group by 669.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 476,098 shares of the company's stock valued at $6,832,000 after purchasing an additional 414,216 shares in the last quarter. Qube Research & Technologies Ltd raised its holdings in shares of Pediatrix Medical Group by 55.4% in the third quarter. Qube Research & Technologies Ltd now owns 1,143,306 shares of the company's stock worth $19,150,000 after buying an additional 407,780 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Pediatrix Medical Group in the second quarter worth $4,248,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new stake in shares of Pediatrix Medical Group during the second quarter worth $4,214,000. Hedge funds and other institutional investors own 97.71% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Jefferies Financial Group reiterated a "buy" rating and set a $27.00 price objective on shares of Pediatrix Medical Group in a research note on Monday, April 20th. Zacks Research lowered Pediatrix Medical Group from a "strong-buy" rating to a "hold" rating in a report on Friday, January 23rd. Deutsche Bank Aktiengesellschaft set a $19.00 target price on Pediatrix Medical Group in a research report on Friday, February 20th. UBS Group cut their price target on Pediatrix Medical Group from $23.00 to $22.00 and set a "neutral" rating on the stock in a report on Tuesday, February 24th. Finally, Weiss Ratings restated a "hold (c+)" rating on shares of Pediatrix Medical Group in a research note on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $21.33.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc NYSE: MD is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.